Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-02-14 3:45 pm Unchanged |
2024-12-31 | 13G | Enliven Therapeutics, Inc. ELVN |
Fairmount Funds Management LLC | 3,202,798 6.600% |
0 (Unchanged) |
Filing History |
| 2025-02-14 09:17 am Sale |
2024-12-31 | 13G | Enliven Therapeutics, Inc. ELVN |
Polar Capital Holdings Plc | 2,389,668 4.890% |
-298,129 (-11.09%) |
Filing History |
| 2024-11-14 5:48 pm Purchase |
2024-09-30 | 13G | Enliven Therapeutics, Inc. ELVN |
Venrock Healthcare Capital Partners III L.P. | 4,026,331 8.500% |
1,071,429 (+36.26%) |
Filing History |
| 2024-11-14 5:46 pm Purchase |
2024-09-30 | 13G | Enliven Therapeutics, Inc. ELVN |
RA Capital Management, L.P. | 1,061,233 2.200% |
1,061,233 (New Position) |
Filing History |
| 2024-11-14 4:24 pm Sale |
2024-09-30 | 13G | Enliven Therapeutics, Inc. ELVN |
Citadel Advisors LLC | 1,734,094 3.700% |
-660,354 (-27.58%) |
Filing History |
| 2024-11-14 4:15 pm Purchase |
2024-09-30 | 13G | Enliven Therapeutics, Inc. ELVN |
Fairmount Funds Management LLC | 3,202,798 6.800% |
1,071,429 (+50.27%) |
Filing History |
| 2024-11-14 4:05 pm Purchase |
2024-09-30 | 13G | Enliven Therapeutics, Inc. ELVN |
Commodore Capital LP | 4,100,000 8.700% |
1,198,184 (+41.29%) |
Filing History |
| 2024-11-13 5:55 pm Purchase |
2024-09-30 | 13G | Enliven Therapeutics, Inc. ELVN |
Polar Capital Holdings Plc | 2,687,797 5.690% |
2,687,797 (New Position) |
Filing History |
| 2024-11-08 2:17 pm Unchanged |
2024-09-30 | 13G | Enliven Therapeutics, Inc. ELVN |
BLACKROCK INC BLK |
2,936,642 6.200% |
0 (Unchanged) |
Filing History |
| 2024-10-24 2:02 pm Purchase |
2024-09-30 | 13G | Enliven Therapeutics, Inc. ELVN |
BLACKROCK INC BLK |
2,936,642 6.200% |
2,936,642 (New Position) |
Filing History |
| 2024-07-29 6:12 pm Sale |
2024-07-25 | 13D | Enliven Therapeutics, Inc. ELVN |
5AM Ventures VI L.P. | 2,304,332 4.900% |
-531,543 (-18.74%) |
Filing History |
| 2024-05-20 4:55 pm Sale |
2024-05-16 | 13D | Enliven Therapeutics, Inc. ELVN |
ORBIMED ADVISORS LLC | 7,918,163 16.800% |
-1,033,300 (-11.54%) |
Filing History |
| 2024-04-15 7:21 pm Sale |
2024-04-11 | 13D | Enliven Therapeutics, Inc. ELVN |
5AM Ventures VI L.P. | 2,835,875 6.100% |
-1,000,100 (-26.07%) |
Filing History |
| 2024-04-04 4:39 pm Purchase |
2024-04-02 | 13D | Enliven Therapeutics, Inc. ELVN |
ORBIMED ADVISORS LLC | 8,951,463 19.200% |
2,124 (+0.02%) |
Filing History |
| 2024-02-16 4:15 pm Sale |
2024-02-14 | 13D | Enliven Therapeutics, Inc. ELVN |
5AM Ventures VI L.P. | 3,835,975 9.300% |
-825,000 (-17.70%) |
Filing History |
| 2024-02-14 8:53 pm Purchase |
2023-12-31 | 13G | Enliven Therapeutics, Inc. ELVN |
Venrock Healthcare Capital Partners III L.P. | 2,954,902 7.200% |
740,760 (+33.46%) |
Filing History |
| 2024-02-14 4:58 pm Purchase |
2023-12-31 | 13G | Enliven Therapeutics, Inc. ELVN |
Citadel Advisors LLC | 2,394,448 5.800% |
95,692 (+4.16%) |
Filing History |
| 2024-02-14 4:05 pm Purchase |
2023-12-31 | 13G | Enliven Therapeutics, Inc. ELVN |
Commodore Capital LP | 2,901,816 7.000% |
819,693 (+39.37%) |
Filing History |
| 2024-02-14 3:45 pm Purchase |
2023-12-31 | 13G | Enliven Therapeutics, Inc. ELVN |
Fairmount Funds Management LLC | 2,131,369 5.200% |
6,744 (+0.32%) |
Filing History |
| 2024-02-14 3:31 pm Purchase |
2023-12-31 | 13G | Enliven Therapeutics, Inc. ELVN |
PFIZER INC PFE |
389,429 0.950% |
389,429 (New Position) |
Filing History |